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To the Editor: Blaustein et al.1 recently reported that a
dosing regimen of 500 mg iron sucrose given intravenously
over 3 h on successive days is safe and effective in
replenishing and maintaining body iron stores.
Preliminary experience on safety and tolerability of high-
dose intravenous iron sucrose administration in iron-
deficient, anemic chronic kidney disease (CKD) patients
with a regimen of iron sucrose 500 mg in 200 ml of normal
saline administered intravenously over 3 h on 2 consecutive
days and once every 3 months subsequently has been
reported by our unit.2 The cumulative data of this
prospective study on high-dose iron sucrose administration
done over 16 months (September 2005 to December 2006)
are shown in Table 1. Adverse events were observed in nine
(12%) patients during nine (5.7%) sessions. No patient had
immediate hypersensitivity reactions. All the patients im-
proved with symptomatic therapy and required observation
for 3–4 h. Six patients, whose first session was complicated
with adverse events, had no problem during the subsequent
session and were successfully, administered iron sucrose as
per this protocol.
An attempt to further simplify this regimen has not been
successful. A high incidence of acute adverse events occurred
when the time of infusion was reduced to 2 h with this dose3
or when total dose administration as 1000 mg infusion was
attempted.1
In conclusion, an accelerated regimen of high-dose
intravenous iron sucrose therapy in CKD patients is safe
and effective in restoring iron stores, and may potentially save
time and improve patient adherence. It may be the optimal
dose regimen that is most practical in predialysis CKD and
continuous ambulatory peritoneal dialysis (CAPD) patients.
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Kidney International (2007) 72, 225; doi:10.1038/sj.ki.5002348
We enjoyed reading the letter to the editor by Dr Vikrant.1
The data presented confirm the safety of this iron sucrose
dosing regimen. The full course of intravenous iron
sucrose (500 mg infused over 3 h on 2 consecutive days)
was well tolerated in 96% of their patients. Similarly, in
our largest study, only 2 of 108 patients (1.8%) had adverse
events attributed to the drug.
Even though the current study2 did not follow iron
parameters or the hemoglobin response to this treatment,
we have shown that this dosing regimen is effective in
replenishing iron stores, and stimulating hematopoiesis in
patients with chronic kidney disease.
1. Vikrant S. Optimum dosage regimen for iron sucrose. Kidney Int 2007; 72: 225.
2. Blaustein DA, Schwenk MH, Chattopadhyay J et al. The safety and efficacy
of an accelerated iron sucrose dosing regimen in patients with chronic
kidney disease. Kidney Int Suppl 2003; 87: S72–S77.
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To the Editor: I would like to raise concerns not addressed in
the RIND (Renagel in new dialysis) extension study
publication.1 The increasingly popular ‘extension study’ is
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Table 1 | High dose iron sucrose administration
Total number of patients 75
Male, n (%) 40 (53.3)
Age (years), mean7s.d. 56.2713.6
Predialysis, n (%) 61 (81.3)
Dialysis – CAPD/APD, n (%) 14 (18.7)
Serum creatinine (mg/dl), mean7s.d. 5.972.8
Hemoglobin (g/dl), mean7s.d. 8.372
Baseline transferring saturation (%), mean7s.d. 17.877.6
Baseline ferritin (ng/ml), mean7s.d. 2187206
Total number of infusions 157
Total iron infused (mg) 78500
Iron per patient (mg), mean7s.d. 10477481
Infusions per patient, mean7s.d. (range) 2.171 (1–6)
Adverse events
Total 9
During the infusiona 3b
After the infusion 6b
APD, automated peritoneal dialysis; CAPD, continuous ambulatory peritoneal
dialysis.
aNecessitating stoppage of the infusion.
bSix patients out of these were successfully re-administered iron sucrose.
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designed to follow patients exiting a randomized trial once
therapies are unrestricted and unblinded, and typically aims
to examine whether benefits seen during the trial persist
following trial completion (for example, HOPE-TOO,2
AIREX,3 SYSTEUR24). They are considered non-interven-
tional, open-label, non-blinded, prospective observational
studies. Block et al.5 are in the unusual position of claiming
benefits (lower mortality with sevelamer vs. calcium-based
phosphate binders) seen during the extension phase, but not
during the randomized phase. No data are provided on
extension phase binder use, or on potential confounders such
as low-density lipoproteins, calcium, phosphate, or para-
thyroid hormone levels.
The authors claim that their results passed proportionality
testing. However, casual review suggests that the hazard
before about 33 months varies substantially from the hazard
after that point. Further details of the model fitting and
diagnostic processes are needed.
The authors attribute the disparate mortality results
between RIND and DCOR (dialysis clinical outcomes
revisited) to differences in study population. When the
results of a small (n¼ 120) non-interventional open-label
extension study examining mortality as a secondary end
point differ from a large (n¼ 2103) randomized trial
examining mortality as the primary outcome, the list of
possible explanations for the disparate results should extend
beyond patient characteristics.
Claims of efficacy made in an extension study but not in a
trial’s randomized phase should be greeted with skepticism.
One possibility is that sevelamer did indeed reduce mortality
in RIND’s extension phase; however, these results should be
considered hypothesis-generating.
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